Engflag

Liviel

Quick links to important sections

Liviel

Liviel_ES

Method of action: Antimalide, Endocrine Therapy, Estrogenic, Estrogen-Progestational, Sex Hormones And Modulators Of The Genital System

Treatment option: Cerebrovascular Accident, Osteoporosis, Prevention Of Osteoporosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Liviel

Quick Facts About Liviel

Property Description
Active ingredient Tibolone
Form Oral tablet
Pharmacological class Hormone Replacement Therapy (HRT); Synthetic steroid
Common use (General) Substitution for hormone deficiency after menopause
Origin Synthetic Norpregnene oxosteroid derivative

What Type of Medicine Is Liviel?

Liviel is a single-component synthetic steroid medication, intended for oral use as an uncoated tablet. This medicine is classified within the field of Hormone Replacement Therapy (HRT) and is generally administered to women who are at least twelve months past their final natural menstrual period. This single-compound structure is a differentiating factor from conventional HRT, which typically requires a separate estrogen and progestogen component.

The core of the product is its active ingredient, Tibolone, which is a synthetic Norpregnene oxosteroid. Tibolone is specifically indicated for the treatment of symptoms due to estrogen deficiency in postmenopausal women. This clinically recognized function confirms the medicine's role in easing common issues linked to low estrogen.

Composition and Unique Activity of Tibolone

The composition of the final product includes only the active ingredient Tibolone, alongside non-active excipients, such as lactose monohydrate, which form the solid oral preparation. Tibolone functions as a prodrug, meaning it requires conversion by the body to become biologically active. This mechanism results in a unique pharmacological profile.

Once absorbed, Tibolone is rapidly converted into three main active metabolites. These metabolites exhibit a balanced spectrum of action, providing estrogenic, progestogenic, and androgenic properties. This unique triple effect is why the medicine is characterized by its ability to selectively support different hormone-dependent tissues in the body. This specific metabolism and resulting tissue-selective pattern differentiate Tibolone from simpler, non-selective hormonal treatments.

What Is the General Purpose of Taking Liviel?

The overarching purpose of taking Liviel is to provide balanced substitution for the natural hormone deficiency that follows menopause. The medicine aids in restoring the hormonal environment required for the maintenance of bodily functions commonly affected by the loss of ovarian hormones. A typical use scenario involves providing sustained relief from the collective effects of postmenopausal estrogen loss. It provides a distinct hormonal substitution option designed to address postmenopausal hormone deficiency using a single synthetic compound.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Liviel?

Adverse Reaction Scope

The official safety profile for Liviel is categorized based on adverse reactions and documented risks across several system-organ classes, as defined by regulatory authorities.

Category Official Regulatory Documentation
Key Adverse Reaction Categories Neoplastic risks, Vascular risks (Venous and Arterial Thromboembolic Events), and common systemic effects affecting the Reproductive, Gastrointestinal, and Skin systems.
Frequency Classification Common (1/100 to < 1/10): Vaginal bleeding or spotting, lower abdominal pain, weight gain, breast pain or tenderness, unnatural hair growth, and various vaginal symptoms. Uncommon (1/1,000 to < 1/100): Acne and nipple pain.
System-Organ Classes Involved Reproductive system and breast disorders, Gastrointestinal disorders, Skin and subcutaneous tissue disorders, Nervous system disorders, Vascular disorders, Neoplasms, and Hepatobiliary disorders.
Serious Adverse Reactions The label documents an increased risk of Stroke (especially in women over 60), increased risk of Breast Cancer, increased risk of Endometrial Cancer and Endometrial Hyperplasia (in women with an intact uterus), and increased risk of Venous Thromboembolism (VTE).

Safety Classifications (High-Level)

Category Official Regulatory Framework
Population-Specific Safety Considerations Older Adults: Risk of stroke is noted to increase in women over 60. Hepatic Impairment: Contraindicated in acute liver disease or if liver function tests have not returned to normal.
Dose- or Exposure-Related Patterns Treatment Initiation: Vaginal bleeding or spotting is typically more prevalent when treatment is first initiated. Long-Term Exposure: The risk of both Endometrial Cancer and Breast Cancer is documented to increase with the duration of use.
Safety-Related Restrictions or Limitations The medicine is contraindicated in cases of known, past, or suspected breast cancer, estrogen-dependent malignant tumors, undiagnosed genital bleeding, previous or current VTE, and arterial thromboembolic disease.

Resulting Safety Structure

  • The safety profile is structured by separating generally experienced Common adverse reactions from the documented Serious risks associated with use.
  • Official classifications detail the specific organ systems and frequency of effects to establish the documented safety scope of the medicine.
  • The profile defines explicit constraints on use based on age, duration, and medical history, which limit the patient population for whom the medicine is officially authorized.

Connection to the overall safety profile:

The regulatory safety information structures the risks by formally categorizing adverse effects into expected occurrences and rare, serious hazards like thromboembolic events and certain cancers. This comprehensive classification, based solely on government-verified findings, defines the essential safety constraints and mandatory limitations for its official use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Liviel (Tibolone) describe specific expected manifestations following an acute overdose, such as the simultaneous ingestion of several tablets. All overdose information is based strictly on the acute toxicity profile documented in governmental prescribing information.

Manifestation Status
Nausea and Vomiting Anticipated clinical signs of acute overdose
Vaginal Bleeding Anticipated clinical sign, noted specifically in females

The regulatory classification of Liviel overdose indicates that toxic symptoms are not expected to occur, even after acute exposure. This assessment is based on non-clinical data confirming the medicine’s very low acute toxicity profile. The event is therefore generally categorized as low-risk for severe or life-threatening outcomes in the acute setting.

Emergency Actions and Management

In the event of an overdose, it is required to seek medical advice for professional assessment. The official guidance states that no specific antidote is known for this medicine. Management is restricted to providing symptomatic treatment and supportive treatment when deemed necessary by a healthcare professional.

When to seek help: Medical attention should be sought for the assessment and management of any of the documented clinical manifestations, including persistent nausea, vomiting, or unexpected vaginal bleeding. The official protocol confirms the need for supportive care to manage the expected, non-toxic symptoms.

Therapeutic Uses of Liviel

Quick Facts: What Liviel Treats

  • Supports the management of type 2 diabetes mellitus to improve glycemic control.
  • Assists in chronic weight management for adults with obesity or those who are overweight with related health conditions.
  • May contribute to a reduced risk of major cardiovascular events in adults with established cardiovascular disease.

What Liviel Treats: Main Uses and Benefits

Liviel is a prescription medication utilized as an addition to dietary and exercise interventions. Its primary approved use is to support the improvement of blood sugar control in adults diagnosed with type 2 diabetes mellitus. It is frequently incorporated into a comprehensive treatment plan to help manage blood glucose levels effectively.

Additionally, the medication is authorized to assist in chronic weight management in specific adult patients. This indication applies to individuals with a diagnosis of obesity or those who are categorized as overweight and have at least one weight-related health condition, such as hypertension or dyslipidemia.

For adults who have type 2 diabetes and documented cardiovascular disease, Liviel is acknowledged for its potential to contribute to a reduction in the occurrence of major adverse cardiovascular events, including non-fatal heart attack or stroke.

Eligibility and Restrictions for Use

The official regulatory criteria for Liviel (Tibolone) strictly define the populations eligible for use and those who must not take the medicine.

Eligibility Scope

Category Regulatory Status
Populations Allowed Postmenopausal women (must be at least 12 months since the last natural period).
Use Not Recommended Children and adolescents (under 18 years); Women over 65 years due to limited data and increased stroke risk.
Contraindicated Status Pregnancy and lactation; Known, past, or suspected breast cancer or other estrogen-dependent malignant tumors.

Condition-Specific Non-Eligibility

Liviel is absolutely contraindicated for patients with specific health conditions, as defined in the official prescribing information:

  • Thromboembolic Risk: Previous or current venous thromboembolism (VTE) or arterial thromboembolic disease (e.g., stroke, myocardial infarction), or known thrombophilic disorders.
  • Organ/Function Status: Acute liver disease or a history of liver disease where liver function tests have failed to return to normal; Porphyria.
  • Gynaecological: Undiagnosed genital bleeding or untreated endometrial hyperplasia.

Connection to the overall eligibility profile: The regulatory documents strictly define who can and cannot use Liviel by establishing clear absolute contraindications based on high-risk conditions sensitive to hormonal influence and risks related to thrombosis or hepatic function. These criteria mandate that the drug's use is strictly limited to the postmenopausal population and prohibits use in patients with specific high-risk medical histories.

What should I know about interactions with other medicines?

Interactions Affecting Drug Exposure

Liviel's official interaction profile is characterized by two main documented types of interaction: those affecting the drug's metabolism and those interfering with the blood clotting process.

Co-administration with certain medicines and herbal products can significantly affect how Liviel works. Regulatory documentation identifies enzyme-inducing substances that may potentially lead to a decrease in the systemic exposure and overall efficacy of Liviel's active metabolites. Such interacting medicinal products include the anti-tuberculosis medicine Rifampicin and the antiepileptic medicines Phenytoin and Carbamazepine. The herbal product St John's wort is also officially documented as a substance that may stop the medicine from working as well due to altered metabolism.

Pharmacodynamic and Procedural Constraints

Liviel is officially documented to influence the body's coagulation system. When co-administered with oral anticoagulants, the medicine may increase the anticoagulant activities. This pharmacodynamic effect necessitates that the benefit-risk assessment for women already receiving anticoagulant treatment requires careful consideration. Additionally, an interaction-related procedural restriction exists: regulatory labels require the temporary discontinuation of Liviel for a period of 4 to 6 weeks prior to any planned elective surgery or anticipated prolonged immobilization, a measure required to mitigate the risk of VTE.

Mechanism of Action

Multi-Hormonal Agonism through Prodrug Metabolism

Liviel's core mechanism relies on its function as a prodrug (Tibolone), which is biologically converted into three main active metabolites. These metabolites act as agonists on the Estrogen Receptor (ER), Progesterone Receptor (PR), and Androgen Receptor (AR), establishing a unique spectrum of multi-hormonal activity across various tissues. This coordinated agonism initiates the signaling sequences necessary for the resulting biological effects.

Tissue-Selective Regulation and Local Enzyme Control

The active compounds achieve tissue-selective effects by modulating key enzymes that regulate local hormone concentrations, specifically inhibiting Estrogen Sulfatase and stimulating Estrogen Sulfotransferase. This mechanism ensures that while ER activation occurs in structural tissues like bone to modulate signaling pathways associated with bone turnover, a localized signal that suppresses proliferation is simultaneously delivered to the endometrium via PR agonism, resulting in endometrial atrophy.

Central Receptor Activation and Modulated Systemic Responses

The estrogenic metabolites activate receptors in the central nervous system, particularly in the hypothalamus, which acts as the body's thermoregulatory center. This central receptor activation modifies the signaling cascade controlling peripheral vasomotor tone and reactivity. The resulting physiological effect is the adjustment of signaling activity influencing the control of peripheral vasomotor responses.

Dosage and Administration Information

How to Use Liviel: General Administration Guidelines

Liviel (Tibolone) is an oral medication that is administered according to specific principles to ensure correct use. The medication is prescribed as a single, uninterrupted daily dose, distinct from sequential hormone replacement therapies.

Administration Protocol

The standard protocol for Liviel is a continuous regimen, meaning the user takes one tablet every day without a break between packs. Treatment for natural menopause is commenced at least 12 months after the final natural menstrual period.

Instruction Category Guideline
Route of Administration Oral
Standard Dosing Schedule One 2.5 mg tablet once daily
Lower Dosing Option 1.25 mg once daily may be used, consistent with the principle of using the lowest effective dose.
Timing and Food Tablets are swallowed whole with water or a drink, preferably at the same time every day, and can be taken with or without food.

Procedural Rules and Duration

For proper administration, the tablets are not crushed or chewed. If a dose is missed, it is taken immediately unless the scheduled time is more than 12 hours overdue, in which case the missed dose is skipped, and the regular schedule resumed; a double dose is not taken.

Treatment is typically initiated with the lowest effective dose and continued for the shortest duration necessary to align with treatment goals. Furthermore, a key administrative principle is that a separate progestogen component is not added to the Liviel regimen, distinguishing its use from conventional combined hormone therapies.

Note on Population: No dose adjustment is necessary for elderly women.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Liviel (Tibolone)

This section summarizes the official research framework—the types of clinical trials and scientific reviews—that health regulators and major guideline bodies have used to evaluate the medicine. This overview research describes what studies explored and what was observed in study populations, without offering clinical advice or personal recommendations.

Evidence for Managing Estrogen Deficiency Symptoms

Liviel was studied for its potential application in addressing outcomes related to physical discomfort and outcomes reflecting daily functioning linked to hormone deficiency after menopause. Research involved Randomized Controlled Trials (RCTs), often involving comparisons against a placebo or an active comparator. Studies report how symptoms evolved in the observed populations, specifically focusing on the change in the frequency and severity of hot flushes and night sweats.

Evidence for Preventing Postmenopausal Bone Loss

Liviel was evaluated in large-scale, long-term RCTs that tracked Bone Mineral Density (BMD) and the clinical endpoint of fracture incidence rate over several years. Data show patterns related to the maintenance or change in BMD in the observed populations. There is limited information for long-term outcomes in women who start the medication without pre-existing bone health issues. The most extensive fracture data results apply only to the specific populations studied, which included a significant proportion of older women (ge 60 years) already diagnosed with osteoporosis.

Studies on Metabolic and Tissue Effects

Research was studied for potential observations related to outcomes related to systemic or functional imbalance, including blood lipid profiles and indicators of insulin resistance ( HOMA-IR). Additionally, research describes studies that monitored the effects on hormone-responsive tissues, such as the uterine lining (endometrium) and breast tissue. Findings were mixed regarding the change in certain lipid markers, and certainty remains low regarding the clinical impact of the observed biomarker changes on long-term cardiovascular health.

Key Studies & References

  1. The effect of tibolone on the risk of vertebral fracture and breast cancer in postmenopausal women with osteoporosis: the LIFT randomised trial

Frequently Asked Questions (FAQ)

Common questions about Liviel (FAQ)

Q: How long does it typically take for Liviel to start working to relieve hot flashes?

According to official product information, an improvement in menopausal symptoms generally begins within a few weeks of starting Liviel. To assess the full effect of the medicine, official information suggests continuing treatment for at least three months.

Q: Does Liviel cause weight gain?

Weight gain is listed as a Common side effect in the regulatory documentation, meaning it may affect up to 1 in 10 women. Some research, referenced in product materials, suggests this increase may be related to changes in fat-free mass (such as muscle and water) rather than solely fat.

Q: What should I do if my tablet is accidentally damaged or broken?

Official guidance specifies that the tablets must be swallowed whole and should not be crushed or chewed, as damaging the tablet may affect its intended function. If the tablet is damaged and cannot be swallowed whole, official regulatory guidance related to a missed dose may be consulted. You should not take a damaged tablet.

Q: Are there any known effects of Liviel on mood, anxiety, or depression?

While specific frequency data for mood, anxiety, or depression may not be generally detailed, the official safety documentation lists Nervous System Disorders and Psychiatric Disorders within the medicine's documented safety scope. This indicates that effects on these systems are within the scope of the medicine's safety profile.

How should Liviel be stored and disposed of?

How to Store and Dispose of Liviel? (Official Regulatory Information)

The storage and disposal instructions for Liviel are defined by government health authorities to ensure the medicine remains safe and effective until its expiration date.

Storage & Disposal Scope Requirement
Labeled Storage Temperature Store the product within the specified temperature range (typically below 25, C or 30, C).
Light/Moisture Protection Keep the medicine protected from excessive heat, moisture, and light.
Handling Constraints Do not freeze the product, as freezing may damage the formulation or container.
Packaging Rules Keep Liviel in its original container with the cap or closure tightly secured.
Child-Protection Rules Keep the medicine out of the sight and reach of children.
Disposal Instructions Do not flush unused or expired medicine down the toilet or pour it into a drain unless instructed otherwise by the FDA or other regulatory agency. Dispose of the product through an authorized pharmaceutical take-back program or as directed by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagAustria

Equivalent of Liviel found in:

A-Z Index: